Wijnand Helfrich Selected Research

Carcinoma (Carcinomatosis)

1/2023	Novel Fab-peptide-HLA-I fusion proteins for redirecting pre-existing anti-CMV T cell immunity to selective eliminate carcinoma cells.
1/2023	Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR.
3/2022	A proof-of-concept study on the use of a fluorescein-based 18F-tracer for pretargeted PET.
8/2021	Bispecific antibody CD73xEpCAM selectively inhibits the adenosine-mediated immunosuppressive activity of carcinoma-derived extracellular vesicles.
1/2015	The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic flux.
9/2014	EpCAM-selective elimination of carcinoma cells by a novel MAP-based cytolytic fusion protein.
4/2014	Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death.
9/2004	Use of the EGP-2/Ep-CAM promoter for targeted expression of heterologous genes in carcinoma derived cell lines.
3/2004	Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Wijnand Helfrich Research Topics

Disease

50	Neoplasms (Cancer) 07/2023 - 04/2002
12	Prostatic Neoplasms (Prostate Cancer) 04/2021 - 07/2009
9	Carcinoma (Carcinomatosis) 01/2023 - 03/2004
7	Melanoma (Melanoma, Malignant) 03/2022 - 11/2010
5	Ovarian Neoplasms (Ovarian Cancer) 07/2023 - 01/2010
3	Neoplasm Metastasis (Metastasis) 01/2022 - 07/2009
3	Ovarian Epithelial Carcinoma 10/2018 - 01/2010
2	Triple Negative Breast Neoplasms 03/2016 - 01/2016
2	Rheumatoid Arthritis 09/2014 - 01/2011
2	Infections 06/2013 - 12/2008
2	Brain Neoplasms (Brain Tumor) 07/2007 - 05/2006
2	Lymphoma (Lymphomas) 02/2007 - 04/2005
2	Leukemia 04/2006 - 04/2005
2	T-Cell Leukemia (Leukemia, T Cell) 04/2006 - 04/2005
1	Photophobia (Light Sensitivity) 02/2024
1	Glioblastoma (Glioblastoma Multiforme) 07/2023
1	Cytokine Release Syndrome 01/2023
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2019
1	Lung Neoplasms (Lung Cancer) 01/2019
1	Bites and Stings (Sting) 01/2019
1	Breast Neoplasms (Breast Cancer) 03/2016
1	Sarcoma (Soft Tissue Sarcoma) 01/2015
1	Colorectal Neoplasms (Colorectal Cancer) 01/2015

Drug/Important Bio-Agent (IBA)

18	Proteins (Proteins, Gene)FDA Link 02/2024 - 03/2004
16	AntigensIBA 03/2022 - 03/2004
15	AntibodiesIBA 07/2023 - 04/2002
9	Epithelial Cell Adhesion MoleculeIBA 07/2023 - 03/2004
8	Immunoglobulin FragmentsIBA 01/2023 - 04/2006
8	LigandsIBA 10/2017 - 03/2005
7	Peptides (Polypeptides)IBA 07/2023 - 07/2009
5	ErbB Receptors (EGF Receptor)IBA 01/2019 - 03/2005
5	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2015 - 04/2002
5	Bombesin Receptors (Bombesin Receptor)IBA 10/2013 - 07/2009
4	RadiopharmaceuticalsIBA 01/2021 - 08/2011
4	TNF-Related Apoptosis-Inducing LigandIBA 08/2016 - 03/2004
4	Monoclonal AntibodiesIBA 01/2015 - 03/2005
4	BombesinIBA 10/2013 - 08/2011
3	beta-apocarotenoid-14',13'-dioxygenase (ADO)IBA 07/2023 - 08/2021
3	Adenosine (Adenocard)FDA LinkGeneric 07/2023 - 08/2021
3	Adenosine Triphosphate (ATP)IBA 07/2023 - 08/2021
3	Surface Antigens (Surface Antigen)IBA 01/2023 - 03/2004
3	chondroitin sulfate proteoglycan 4IBA 11/2019 - 01/2016
3	Rituximab (Mabthera)FDA Link 01/2019 - 08/2006
3	VaccinesIBA 10/2018 - 01/2010
3	TNF-Related Apoptosis-Inducing Ligand ReceptorsIBA 02/2016 - 03/2004
2	Immune Checkpoint InhibitorsIBA 01/2023 - 11/2019
2	Antigen-Antibody Complex (Immune Complex)IBA 01/2023 - 04/2002
2	Cytotoxins (Cytolysins)IBA 01/2023 - 05/2006
2	AzidesIBA 04/2021 - 08/2020
2	Alkynes (Acetylenes)IBA 04/2021 - 08/2020
2	Bispecific AntibodiesIBA 01/2019 - 05/2008
2	Glycoproteins (Glycoprotein)IBA 06/2017 - 08/2008
2	Immunoglobulin G (IgG)IBA 01/2015 - 04/2002
2	Immunotoxins (Immunotoxin)IBA 10/2014 - 05/2013
2	temoporfinIBA 10/2014 - 05/2012
2	Radioisotopes (Radionuclides)IBA 06/2014 - 08/2012
2	Technetium (Technetium 99m)IBA 10/2013 - 08/2011
2	bombesin (7-14)IBA 10/2013 - 08/2011
2	tricineIBA 10/2013 - 08/2011
2	rimcazoleIBA 09/2013 - 11/2010
2	Death Domain ReceptorsIBA 05/2013 - 02/2007
2	Gefitinib (Iressa)FDA Link 08/2006 - 03/2005
2	Bortezomib (Velcade)FDA Link 08/2006 - 04/2006
1	SolitomabIBA 01/2023
1	EnzymesIBA 01/2023
1	Fluorescein (Funduscein)FDA LinkGeneric 03/2022
1	IsotopesIBA 03/2022
1	Cancer VaccinesIBA 01/2022
1	RNA (Ribonucleic Acid)IBA 01/2022
1	Pregnancy-Associated Plasma Protein-A (PAPP-A)IBA 01/2022
1	5'-Nucleotidase (5' Nucleotidase)IBA 08/2021
1	Androgen Receptors (Androgen Receptor)IBA 01/2021
1	enzalutamideIBA 01/2021
1	Viral ProteinsIBA 01/2020
1	Programmed Cell Death 1 ReceptorIBA 11/2019
1	blinatumomabIBA 01/2019
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2019
1	durvalumabIBA 01/2018
1	Fluorescein-5-isothiocyanate (FITC)IBA 10/2017
1	Granzymes (Granzyme)IBA 03/2016
1	human ERBB2 proteinIBA 01/2016
1	Estrogens (Estrogen)FDA Link 01/2016
1	Progesterone FDA LinkGeneric 01/2016
1	CalreticulinIBA 01/2015
1	Therapeutic UsesIBA 01/2015
1	Immunoglobulin Fab FragmentsIBA 01/2015
1	Complement System Proteins (Complement)IBA 01/2015
1	Galectins (Galectin)IBA 01/2015
1	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 11/2014
1	Photosensitizing Agents (Photosensitizers)IBA 10/2014
1	Bleomycin (Blenoxane)FDA LinkGeneric 10/2014

Therapy/Procedure

19	Therapeutics 07/2023 - 09/2004
12	Immunotherapy 01/2023 - 04/2002
4	Drug Therapy (Chemotherapy) 10/2018 - 01/2010
2	Computer-Assisted Surgery (Image Guided Surgery) 11/2014 - 06/2014
2	Radiotherapy 10/2013 - 05/2006
1	Cytoreduction Surgical Procedures 01/2022
1	Hyperthermic Intraperitoneal Chemotherapy 01/2022
1	Aftercare (After-Treatment) 01/2018
1	Photochemotherapy (Photodynamic Therapy) 10/2014